Exercise Interventions for Improving Health in Breast Cancer Survivors
NCT ID: NCT06376578
Last Updated: 2024-04-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2018-09-05
2020-01-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Randomized Two-Arm Proof of Concept Study Testing A Novel Approach to Exercise Promotion Based on Affect-regulation
NCT06258993
Narrative Visualization for Breast Cancer Survivors' Physical Activity
NCT03612596
Promoting Activity in Cancer Survivors
NCT03060941
Lifestyle Program (Scalable Nutrition and Physical Activity) for the Improvement of Nutrition and Physical Activity in Stage 0-III Breast Cancer Survivors
NCT04200482
Impact of Personalized and Remote Support Centered on Exercise and Physical Activity for Breast Cancer Patients
NCT04536584
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Remotely-supported exercise group:
The remotely-supported group will received a target for a total duration of exercise each week (outdoor walking) progressing in duration from 105 to 150-min and 55% to 70% of V̇O2max. By week 7, the exercise prescription will align with common physical activity recommendations. Participants will be advised how they can break down their target into manageable bouts (e.g., 3 × 35 min walks = 105-min in week 1) and will be instructed to accumulate exercise with a minimum bout-length of 10-min. Intensity will be checked by participants using heart-rate thresholds that corresponded to their V̇O2max. Participants will take part in a weekly 30-min telephone calls to discuss the exercise they have completed, as documented by an internet-based data visualisation platform with data input from a wrist worn fitness tracker that records accelerometry data and heart rate
Partly-supervised exercise group:
The partly-supervised exercise group will undertake 2 supervised (laboratory-based treadmill and cycle ergometer exercise) and 1 unsupervised session per week (e.g., outdoor walking) progressing from 35 to 50-min and 55% to 70% of V̇O2max. By week 7, the exercise prescription will align with common physical activity recommendations. During supervised laboratory sessions, intensity will be confirmed and adjusted using indirect calorimetry. The intensity of unsupervised exercise sessions will be recorded using a chest-worn heart rate monitor.
Participant characterisation:
Participants will attend a laboratory for characterisation before and after the intervention (within 7 days) following a 10 hour overnight fast and after refraining from exercise, alcohol, and caffeine in the prior 24 hours. Body mass and height will be measured with the participant wearing light clothing. Body composition monitor. Dual-energy X-ray absorptiometry will be used to quantify fat mass, lean mass, and bone mineral density parameters. Blood pressure will be measured using an automated sphygmomanometer following 15 minutes rest in the supine position.
Physical function will be assessed using three tests. First, the 6-minute walk test, whereby participants will walk as far as possible in 6-minutes between two cones placed 7 meters apart. Second, the sit to stand test, whereby participants will perform as many sit-to-stands as possible in 30 seconds (i.e., seated on a standardised chair, rising to reach full knee extension, returning to a seated position, arms folded across the chest). Third, the 8 foot up timed up and go test, whereby participants will rise from being in a seated position on a standardised chair, walk 8 feet, and return to a seated position as quickly as possible.
Cardiorespiratory fitness will be assessed using a treadmill-based maximal walking exercise test to exhaustion comprising 3-minute stages, beginning at 2.7 kph with a 1% gradient and increasing by 1.3 kph until 6.6 kph, with further intensity increments via increasing gradient by 2%. During the final minute of each stage, heart rate will be measured using telemetry and rating of perceived exertion will be recorded. Expired air samples will be collected using Douglas bags during the final minute of each stage. Oxygen and carbon dioxide within each bag will be analysed using a gas analyser and volume and temperature of the air will be assessed using a digital thermometer and dry gas meter.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Partly supervised, prescribed exercise group
The partly-supervised, prescribed exercise group will be required to undertake two supervised exercise sessions and one unsupervised exercise session at home or in your local area each week. Supervised sessions will consist of exercising on both a treadmill and a stationary exercise bike. The intervention will be progressive, increasing in intensity and duration.
Exercise intervention
Exercise training will progress incrementally, increasing the duration of exercise on the treadmill by 5 minutes every 2 weeks whereby the final duration on the treadmill will be 35 minutes and the total duration will map onto recommended guidelines of 150 minutes per week. Throughout the 8-weeks, the duration of exercise on the cycle ergometer will remain at 15 minutes. Exercise intensity will progress throughout the 8-week intervention on both the treadmill and the cycle ergometer by 5% every 2 weeks, whereby exercise during the final week will be at 70% VO2max.
Technology enabled, remotely delivered exercise group
The technology enabled, remotely delivered exercise group will receive information and advice about exercise that could be undertaken at home or in their local area. In addition, participants will received a Polar A370 fitness tracker wristwatch with heart rate monitoring chest strap. Participants will take part in exercise each week (most likely walking) which will increase in duration over 8-weeks from 105 minutes each week to 150 minutes each week. Each week a member of the research team will have a telephone call with the participant to discuss the exercise prescription.
Polar A380 wristwatch physical activity tracker
The research team will monitor individual exercise training weekly using virtual/electronic methods and a 30 minute telephone call. The researcher will provide feedback about how the participant's activity compares to physical activity recommendations, and encouragement and support will be provided verbally.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exercise intervention
Exercise training will progress incrementally, increasing the duration of exercise on the treadmill by 5 minutes every 2 weeks whereby the final duration on the treadmill will be 35 minutes and the total duration will map onto recommended guidelines of 150 minutes per week. Throughout the 8-weeks, the duration of exercise on the cycle ergometer will remain at 15 minutes. Exercise intensity will progress throughout the 8-week intervention on both the treadmill and the cycle ergometer by 5% every 2 weeks, whereby exercise during the final week will be at 70% VO2max.
Polar A380 wristwatch physical activity tracker
The research team will monitor individual exercise training weekly using virtual/electronic methods and a 30 minute telephone call. The researcher will provide feedback about how the participant's activity compares to physical activity recommendations, and encouragement and support will be provided verbally.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* History of previous stage I-III invasive breast cancer
* No history of metastatic cancer
* No significant cardiac co-morbidity
* No diagnosis of bilateral breast cancer
* \> 2 months from surgery, chemotherapy and radiotherapy treatments, however patients continuing with endocrine therapy will be included.
* BMI 20 \> \<35 kg.m2
* Oncologist clearance
* Pass physical activity readiness questionnaire (PAR-Q)
* Last menstrual period \>1 year ago
Exclusion Criteria
* Previous superficial basal cell carcinoma of the skin or prior carcinoma-in situ (including ductal carcinoma in situ/lobular carcinoma in situ of breast) is allowed
* Cardiovascular Disease
* Severe hypertension (\>200/120 mmHg)
* 5+ years since last treatment
* Active infection at recruitment
* Undertaking regular, structured, exercise training defined as self-reported structured physical activity lasting \> 30 minutes on two or more occasions per week (measured before the first visit using the international physical activity questionnaire (IPAQ))
* Contraindication to undertaking an exercise programme including previously diagnosed significant osteoporosis or other co-morbidities at the oncologist's discretion
35 Years
69 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Bath
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
James Turner, Ph.D., FHEA
Dr James Turner
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Bath
Bath, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
245256
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.